Senseonics (NYSE:SENS) this week announced that it partnered with Geo-Med to provide access to the Eversense continuous glucose monitor to more than 9 million veterans and U.S. government staff. The company’s Eversense device is the first CGM system to feature an implantable sensor that can be worn for up to 90 days. The system includes a […]
Senseonics
Senseonics extends distribution agreement with Roche Diabetes Care
Senseonics Holdings (NYSE-American: SENS) — maker of an implantable continuous glucose monitoring system for people with diabetes — has extended its distribution agreement with Roche Diabetes Care. The agreement extension, announced yesterday, has Roche continuing as Senseonics’ exclusive distributor in Europe, the Middle East and Africa — excluding Scandinavia and Israel. The agreement also adds 17 […]
Senseonics wins MRI-safe FDA nod for Eversense CGM
Senseonics announced that it has received notice from the FDA that its Eversense sensor no longer has to be removed for MRI scanning. “Based on our testing, we have demonstrated hat it is safe for patients to leave the Eversense Sensor in place, even when they need to have an MRI,” Tim Goodnow, president and […]
Senseonics touts first U.S. trial implant of 180-day CGM
Senseonics (NYSE:SENS) said yesterday that its Eversense XL 180-day continuous glucose sensor was implanted into the first participant of a trial designed to support a pre-market application to the FDA. The company’s 180-patient Promise trial is slated to study the safety and efficacy of the Eversense device in people with diabetes over 180 days. Senseonics also […]
Senseonics reports mixed Q3 results
Shares in Senseonics (NYSE:SENS) fell today after the medical device maker missed EPS expectations but met sales estimates on Wall Street with its third quarter financial results. The Germantown, Md.-based company posted a net loss of -$31.9 million on sales of $5.2 million for the 3 months ended Sept. 30. Quarterly net losses were up 83% on […]
Senseonics wins another FDA approval for its implantable CGM
Senseonics (NYSE:SENS) said this week that it won another FDA approval for its implantable continuous glucose monitoring system, giving nurse practitioners and physicians assistants the ability to implant and remove the Eversense device. When the product was first approved by the FDA in June, only trained physicians were allowed to conduct the sensor insertion and removal […]
Senseonics wins coverage from Aetna for Eversense glucose monitor
Senseonics (NYSE:SENS) said this week that won coverage from health plan provider Aetna for its Eversense continuous glucose monitoring system. Aetna provides coverage for roughly 22 million people in the U.S., according to Senseonics, making it the third largest commercial health plan provider in the country. “We are pleased that one of the largest national payers […]
Senseonics launches Eversense implantable glucose monitor
Senseonics (NYSE:SENS) said today that its Eversense continuous glucose monitoring system is available at clinics across the U.S. The Germantown, Md.-based company also touted that it won coverage for its CGM with Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey. Senseonics’ 90-day, implantable CGM won FDA approval in June this year. […]
Senseonics inks diabetes management deal with Glooko
Senseonics (NYSE:SENS) said today that it inked a global deal to integrate its Eversense continuous glucose monitoring system with Glooko‘s diabetes data management tech. Users will be able to sync data from their Eversense CGM directly into Glooko’s platform and view historical glucose trends, as well as receive real-time readings from their Eversense mobile app, according […]
Senseonics closes $150m public offering
Senseonics (NYSE:SENS) said today that it closed an underwritten public offering of its common stock, reeling in $149.5 million in total proceeds. The Germantown, Md.-based company plans to use its newly-acquired funds to support the commercialization of its implantable continuous glucose monitoring system, Eversense. “We are pleased with the results of this transaction and the […]
